Technology
Health
Pharmaceutical
Zymeworks
$17.649876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$17.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.04 (-0.23%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!
About
Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
CEO
Employees
183
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
565.34M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
143.30K
High Today
$18.17
Low Today
$17.57
Open Price
$17.97
Volume
17.78K
52 Week High
$29.00
52 Week Low
$10.72
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
Canada
North America
News
Financial PostMay 23
Zymeworks Announces Corporate Update Conference Call
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships. Zymeworks will host a webcast and conference call on Wednesday, May 29, 2019 at 8:30am ET (5:30am PT...
Seeking AlphaMay 16
GSK expands collaboration with Zymeworks
GlaxoSmithKline (NYSE:GSK) has expanded the scope of its 2016 licensing and collaboration partnership with Zymeworks (NYSE:ZYME), now enabling access to the latter's heavy-light chain pairing technology which is part of its Azymetric platform.
Price Paid on Robinhood
12% Higher
Right Now
52 Week Low
$10.72
Average Price Paid
$15.74
52 Week High
$29.00
Earnings
-$0.83
-$0.13
$0.58
$1.28
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 31, After Hours